NL-OMON46194
Recruiting
N/A
Personalizing therapy of urogenital cancer by metastatic tissue Immune profiling, Organoid culture, and NExt genERation sequencing - PIONEER
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Urigenital cancer
- Sponsor
- Radboud Universitair Medisch Centrum
- Enrollment
- 150
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Patients with metastasized bladder cancer or prostate cancer
Exclusion Criteria
- •\- Comorbidity that interferes with the safe removal of extra tissue.
- •\- Objection against anonymized storage of tissue for an unlimited period of time.
- •\- Objection against disclosure of relevant incidental findings (DNA sequencing).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Tailored treatment of prostate cancer by biomarkers: PROCABIOprostate cancerProstate carcinoma1003858810036958NL-OMON33361Erasmus MC, Universitair Medisch Centrum Rotterdam50
Recruiting
N/A
Personalized Treatment of Urogenital Cancers Depends on the MicrobiomeMicrobial DiseaseNCT03962920Zealand University Hospital28
Completed
N/A
Development of urothelial cancer-Specific mRNA and miRNA Assay in Human Urinary Exosomes and MicrovesiclesBladder CancerJPRN-UMIN000030054Hokkaido University Graduate School of Medicine600
Recruiting
Phase 1
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 TrialProstate cancerTherapeutic area: Diseases [C] - Neoplasms [C04]CTIS2022-501551-90-00Gasthuiszusters Antwerpen493
Completed
N/A
Focal therapy of localized prostate cancer using mpMRI/TRUS-guided high intensity focused ultrasound (HIFU) technologyC61Malignant neoplasm of prostateDRKS00007105Klinik für Urologie, Universitätsmedizin Mannheim50